Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.
Sponsor: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
Terminated
low recruitment rate exacerbated by manufacturing shortage and price increase of hydroxychloroquine.
This PHASE3 trial investigates Antiphospholipid Syndrome and is currently terminated or withdrawn. AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking leads this study, which shows 13 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Jun 2021 — Oct 2021 [monthly]
Terminated PHASE3
▶ Show 8 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Dec 2017 — May 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — Dec 2017 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Feb 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
- Hospital for Special Surgery, New York
- The New York Community Trust
For direct contact, visit the study record on ClinicalTrials.gov .